Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

rowex ltd - acetylsalicylic acid - gastro-resistant tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid - antithrombotic agents: platelet aggregation inhibitors excl. heparin - it is used for: secondary prevention of myocardial infarction, prevention of cardiovascular morbidity in patients suffering from stable angina pectoris, history of unstable angina pectoris, except during the acute phase, prevention of graft occlusion after coronary artery bypass grafting (cabg), coronary angioplasty, except during the acute phase, secondary prevention of transient ischaemic attacks (tia) and ischaemic cerebrovascular accidents (cva), provided intracerebral haemorrhages have been ruled out.

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - acetylsalicylic acid - gastro-resistant tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - acetylsalicylic acid - gastro-resistant tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

rowex ltd - clopidogrel hydrochloride - film-coated tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; clopidogrel

Singapura - Inggris - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - clopidogrel hydrogen sulphate eqv clopidogrel - tablet, film coated - 75 mg - clopidogrel hydrogen sulphate eqv clopidogrel 75 mg

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - clopidogrel - film-coated tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; clopidogrel

Uni Eropa - Inggris - EMA (European Medicines Agency)

hcs bvba  - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for further information please refer to section 5.1.

Uni Eropa - Inggris - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - combinations - clopidogrel/acetylsalicylic acid teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid teva is a fixed‑dose combination medicinal product for continuation of therapy in:non‑st segment elevation acute coronary syndrome (unstable angina or non‑q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Israel - Inggris - Ministry of Health

eli lilly israel ltd - prasugrel as hydrochloride - film coated tablets - prasugrel as hydrochloride 5 mg - platelet aggregation inhibitors, excl. heparin - effient, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci).the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 or weight below 60 kg.

Israel - Inggris - Ministry of Health

eli lilly israel ltd - prasugrel as hydrochloride - film coated tablets - prasugrel as hydrochloride 10 mg - platelet aggregation inhibitors, excl. heparin - effient, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome ( i.e. unstable angina, non-st segment elevation myocardial infarction [ua/nstemi] or st segment elevation myocardial infarction [stemi] undergoing primary or delayed percutaneous coronary intervention (pci). the increased efficacy should be balanced with the increased risk in patients with bleeding tendencyin those who had tia/cva in the past and in those above the age of 75 or weight below 60 kg.